---
layout: post
title: "Workshop To Enhance Clinical Study Diversity; Public Workshop; Request for Comments"
date: 2026-02-05 18:56:34 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-18149
original_published: 2023-08-23 00:00:00 +0000
significance: 8.00
---

# Workshop To Enhance Clinical Study Diversity; Public Workshop; Request for Comments

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 23, 2023 00:00 UTC
**Document Number:** 2023-18149

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing a public workshop entitled "Workshop To Enhance Clinical Study Diversity." This public workshop will satisfy a mandate of the Food and Drug Omnibus Reform Act of 2022 (FDORA) for FDA to convene one or more public workshops to solicit input from various stakeholders on enhancing diversity in clinical studies.The public workshop will be convened and supported by a cooperative agreement between FDA and the Clinical Trials Transformation Initiative and will solicit input from interested parties on increasing the enrollment of historically underrepresented populations in clinical studies and encouraging clinical study participation that reflects the prevalence or incidence of the disease or condition among demographic subgroups, where appropriate.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/23/2023-18149/workshop-to-enhance-clinical-study-diversity-public-workshop-request-for-comments)
- API: https://www.federalregister.gov/api/v1/documents/2023-18149

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
